Biotech Values

[drbio45]

ohrp...I do not think this is a placebo effect

http://www.fleyedocs.com/current-upcoming-clinical-trials/

From Dr. Randy Katz:


We have one study for wet AMD for sub responders to Lucentis, Avastin, Eyelea or Macugen. This study is for patients who have received 3-10 injections in the past year with the last 3 treatments being with the same drug consistently.

We are now enrolling for treatment naïve wet AMD patients for Eyelea. Phase IV, participants are guaranteed to get Eyelea. No AMD in the fellow eye allowed.

Our second study for wet AMD using eye drops that potentially will cut down on the need for monthly injections is still enrolling participants. The study combines Lucentis and the study eye drops Squalamine Lactate, administered topically. “The hope is that with the administration of these eye drops twice daily, the frequency of intravitreal injections will be greatly reduced,” said Dr. Katz. “The results thus far have been amazing, as many of the study participants have been able to forego monthly injections as a result of the drug combination used in the nine month study.”

The study is placebo controlled (for the drops). All receive Lucentis but need to be covered by insurance to pay for the Lucentis. Participants need to come for 12 visits over 38 weeks.